Breast Cancer | Specialty

Dr. Anees B. Chagpar on the Hottest Topics in Breast Cancer Management

September 23rd 2016

Anees B. Chagpar, MD, associate professor of Surgery (Oncology), director of The Breast Center at Smilow Cancer Hospital at Yale-New Haven, Yale Cancer Center, explains some of the most discussed topics in breast cancer. Chagpar was recently the chair at the State of the Science Summit on Breast Cancer held Sept. 15.

Dr. Harigopal on Advances With Breast Cancer Pathology

September 21st 2016

Malini Harigopal, MD, associate professor of Pathology, interim director of Breast Pathology, Yale School of Medicine, Yale Cancer Center, discusses the advancements in the pathology of breast cancer.

Dr. Sanft on HER2-Positive Breast Cancer

September 21st 2016

Tara Sanft, MD, assistant professor of medicine, medical director of adult survivorship for the Yale Cancer Center Survivorship Clinic, discuses advancements in HER2-positive breast cancer.

Dr. Hofstatter on Identifying High-Risk Patients in Breast Cancer

September 21st 2016

Erin Wysong Hofstatter, MD, associate professor, co-director, Cancer Genetics and Prevention Program, Yale Cancer Center, discusses the important factors for identifying potentially high-risk patients in breast cancer.

FDA Accepts Neratinib NDA for HER2-Positive Breast Cancer

September 20th 2016

The FDA has accepted a new drug application for neratinib as an extended adjuvant therapy for patients with HER2-positive breast cancer following prior treatment with postoperative trastuzumab.

CHMP Issues Positive Opinion for Palbociclib in HR+/HER2- Breast Cancer

September 17th 2016

The Committee for Medicinal Products for Human Use has recommended approval of palbociclib for patients with HR-positive, HER2-negative metastatic breast cancer, either in combination with an aromatase inhibitor in the frontline setting, or combined with fulvestrant after progression on endocrine therapy.

Dr. Yardley on Emerging Agents in HER2-Positive Breast Cancer

September 15th 2016

Denise A. Yardley, MD, senior investigator, Breast Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses some of the emerging agents in HER2-positive breast cancer.

Biology of Triple-Negative Breast Cancer Crucial for Most Effective Treatment

September 15th 2016

It is important to achieve a complete and thorough understanding of triple-negative breast cancer in order to most effectively treat patients.

Dr. Cynthia Ma on Immunotherapy in TNBC

September 15th 2016

Dr. O'Shaughnessy on Precision Medicine in Triple Negative Breast Cancer

September 14th 2016

Joyce O'Shaughnessy, MD, co-chair, breast cancer research, chair breast cancer at Baylor University Medical Center, discusses precision medicine in triple negative breast cancer.

Dr. White on Omitting Radiation in Breast Cancer

September 13th 2016

Julia White, MD, professor of Radiation Oncology, Ohio State University Comprehensive Cancer Center, discusses the omission of radiation therapy for patients with breast cancer.

Dr. Mamounas on Adverse Events With Mastectomy in Breast Cancer

September 8th 2016

Eleftherios P. Mamounas, MD, surgical oncologist, UF Health Cancer Center - Orlando Health, discusses the common adverse events associated with mastectomy and breast conserving surgery for patients with breast cancer, as well as how oncologists can best manage these toxicities.

Obesity an Increasing Incidence in Breast Cancer, CRC Survivors

September 3rd 2016

Obesity is more prevalent in cancer survivors, specifically in those with a history of breast or colorectal cancer, compared with those without any history of disease.

Dr. Sunil Verma on Treatment for Early HER2+ Breast Cancer

September 2nd 2016

Dr. Kathy S. Albain on Breast Cancer Risk After 5 Years of Tamoxifen

September 1st 2016

Dr. White on Relationship Between Multigene Assays and RT in Breast Cancer

September 1st 2016

Julia White, MD, professor of Radiation Oncology, Ohio State University Comprehensive Cancer Center, discusses the relationship between multigene assays and radiation therapy in patients with breast cancer.

Dr. O'Connor on Ongoing Breast Cancer Research

August 30th 2016

Kathleen L. O'Connor, MD, professor, associate director of Cancer Education, Department of Molecular and Cellular Biochemistry, University of Kentucky Markey Cancer Center, discusses the ongoing research in the field of breast cancer.

Dr. Chandarlapaty on Role of the PI3K Pathway in Breast Cancer

August 29th 2016

Sarat Chandarlapaty, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of the PI3k pathway in patients with metastatic breast cancer.

Study Confirms MammaPrint's Accuracy in Assessing Treatment for Early Breast Cancer

August 26th 2016

Approximately 46% of patients with breast cancer at high risk for recurrence but low genomic risk with the 70-gene breast cancer recurrence assay (MammaPrint) might not require adjuvant chemotherapy.

Dr. Robson on Breast Cancer Risk Management

August 26th 2016